| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Registrant’s telephone number, including area code: (615) 733-4730 |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
The second-half ramp we anticipated materialized as Harrow reported record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year. Branded products led the way, providing $83.5 million in revenue, up 62% year ... |
| 05 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise |
| 04 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. (the “Company”). |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
The first half of 2026 was about driving demand and fine-tuning business rules; the second half is about converting growing demand into revenue and profits. The balance of this Letter to Stockholders describes why I believe we are set up... |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
NASHVILLE, Tenn., August 6, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline so... |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, Harrow, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The number of shares of common stock entitled to vote at the Annual Meeting was 37,273,420. The number of shares of commo... |
| 03 Jun 2026 |
8-K: Regulation FD Disclosure
Attached as Exhibit 99.1 to this Current Report on Form 8-K is a corporate presentation of Harrow, Inc. (the “Company”), dated June 2026, which may be used from time to time by the Company’s management at investor conferences and in meet... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
The first quarter of 2026 saw unprecedented market demand for VEVYE® and an unavoidable modeling challenge related to our new commercial coverage. While we were pleased with the former (the unprecedented demand for VEVYE), the latter res... |
| 27 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Harrow, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the “Representative”), ... |
| 24 Mar 2026 |
8-K: Other Events
NASHVILLE, Tenn., March 24, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $50.0 million aggregate pri... |
| 24 Mar 2026 |
8-K: Other Events
NASHVILLE, Tenn., March 24, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additi... |
| 10 Mar 2026 |
8-K: Regulation FD Disclosure
The Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a corporate presentation that may be used by management in connection with investor conferences and meetings with investors. |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Today, Harrow reported record fourth quarter revenues of $89.1 million, a 33% increase over the prior year’s fourth quarter revenues of $66.8 million, and a sequential increase of 24% from the third quarter 2025 revenues. For the full ye... |
| 02 Feb 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
NASHVILLE, Tenn., February 2, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today reaffirmed its full-year 2025 revenue guidance of between $270-280 million, and highlighted... |
| 18 Nov 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities +1 more
NASHVILLE, Tenn., November 18, 2025 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a cl... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
During the third quarter of 2025, Harrow continued to emerge as a leader in providing ophthalmic disease management solutions in North America. We’re making progress, but much work remains to be done as we advance the standard of care in... |
| 06 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Frank Mullery Appointed Chief Executive Officer of ImprimisRx |
| 29 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On September 26, 2025, Harrow, Inc., (the “Company”), and subsidiaries of the Company as guarantors (“Subsidiary Guarantors”) entered into a Credit Agreement (the “New Credit Agreement”) with Fifth Third Bank, National Association, as ad... |
| 26 Sep 2025 |
8-K: Regulation FD Disclosure
On September 26, 2025, Harrow, Inc. (the “Company”) hosted its Investor Day. In connection with this event, the Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a copy of the investor presentation (the “Presentati... |
Loading...